Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabella Montagna

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|September 7, 2016
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialDave Singh, Alberto Papi, Massimo Corradi, et al.
ERJ Open Research|February 13, 2023
Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trialsEva Topole, Sonia Biondaro, Isabella Montagna, et al.
Lancet (London, England)|April 8, 2017
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialJørgen Vestbo, Alberto Papi, Massimo Corradi, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2025
Opportunities in Development of Patient-Centric and Decentralized Clinical Trials: Insights from Patients and Healthcare Professionals in Respiratory and Rare DiseasesMarisa Minetti, Eva Topole, Ilaria Rondinone, et al.
Lancet (London, England)|February 13, 2018
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialAlberto Papi, Jørgen Vestbo, Leonardo Fabbri, et al.
International Journal of Molecular Sciences|July 9, 2022
11β-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic InflammationChloe G Fenton, Ana Crastin, Claire S Martin, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|September 7, 2016
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialDave Singh, Alberto Papi, Massimo Corradi, et al.
ERJ Open Research|February 13, 2023
Artificial intelligence based software facilitates spirometry quality control in asthma and COPD clinical trialsEva Topole, Sonia Biondaro, Isabella Montagna, et al.
Lancet (London, England)|April 8, 2017
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialJørgen Vestbo, Alberto Papi, Massimo Corradi, et al.
Therapeutic Innovation & Regulatory Science|June 20, 2025
Opportunities in Development of Patient-Centric and Decentralized Clinical Trials: Insights from Patients and Healthcare Professionals in Respiratory and Rare DiseasesMarisa Minetti, Eva Topole, Ilaria Rondinone, et al.
Lancet (London, England)|February 13, 2018
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialAlberto Papi, Jørgen Vestbo, Leonardo Fabbri, et al.
International Journal of Molecular Sciences|July 9, 2022
11β-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic InflammationChloe G Fenton, Ana Crastin, Claire S Martin, et al.
Pageof 1